Clinical Trials
19 trialsNCT05429320 2026-02-02
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02389517 2026-01-22
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
Phase 2 Completed
NCT02666898 2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2 Completed
NCT02458014 2025-09-23
Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04827745 2025-07-03
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
University of Maryland, Baltimore
Phase 2 Completed
NCT02988466 2025-05-28
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT03367299 2025-01-22
LAL2317
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT04716075 2025-01-16
ACALLO
Polish Lymphoma Research Group
Phase 2 Completed
NCT02169609 2024-04-22
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Phase 2 Completed
NCT03096782 2023-10-11
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04712942 2023-08-21
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
University of Leipzig
Phase 2 Completed
NCT03109093 2023-03-21
Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia
Goethe University
Phase 2 Completed
NCT00199030 2023-03-20
Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath
Goethe University
Phase 2 Completed
NCT02067143 2021-09-08
LAL1913
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT01207388 2020-02-10
BLAST
Amgen Research (Munich) GmbH
Phase 2 Completed
NCT01401959 2018-06-15
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00560794 2015-01-26
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Research (Munich) GmbH
Phase 2 Completed
NCT00267085 2012-08-07
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00358072 2010-12-29
Treatment of Adult ALL With an MRD-directed Programme.
Northern Italy Leukemia Group
Phase 2 Completed